TY - JOUR
T1 - Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
AU - Karakashev, Sergey V.
AU - Reginato, Mauricio
N1 - Karakashev, Sergey V Reginato, Mauricio J R01 CA155413/CA/NCI NIH HHS/United States Journal Article Review New Zealand 2015/09/01 Cancer Manag Res. 2015 Aug 12;7:253-64. doi: 10.2147/CMAR.S58285. eCollection 2015.
PY - 2015/8
Y1 - 2015/8
N2 - Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.
AB - Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance.
KW - Hif-1 apoptosis cancer chemoresistance signaling
U2 - 10.2147/cmar.S58285
DO - 10.2147/cmar.S58285
M3 - Article
SN - 1179-1322
VL - 7
SP - 253
EP - 264
JO - Cancer Management and Research
JF - Cancer Management and Research
ER -
